Treatment-naive patients who did not respond to immunotherapy
Patient . | Disease duration prior to treatment . | Transfusions prior to treatment, no. . | Treatment type . | MCF ratio . |
---|---|---|---|---|
1 | 3.5 mo | 4 | ATG/CSA | 1 |
2 | 5 mo | 19 | ATG/CSA | 0.58 |
3 | 3 mo | 4 | ATG/CSA | 1 |
4 | 10 y | 2 | CTX | 0.9 |
5 | 3 mo | 3 | ATG/CSA | 1 |
6 | 8 y | 4 | ATG/CSA | 0.52 |
7 | 4 mo | 20 | ATG/CSA | 0.36 |
8 | 8 y | 3 | CTX | 0.54 |
9 | 2.5 mo | 4 | CTX | 0.28 |
10 | 4 y | 11 | ATG/CSA | 0.58 |
11 | 3 mo | 2 | ATG/CSA | 0.39 |
12 | 3 mo | 9 | ATG/CSA | 1 |
13 | 3 mo | 3 | ATG/CSA | 1 |
14 | 3 wk | 3 | ATG/CSA | 1 |
15 | 1 mo | 2 | ATG/CSA | 0.7 |
16 | 2 wk | 4 | ATG/CSA | 0.8 |
17 | 3 mo | 5 | ATG/CSA | 1.2 |
18 | 2 mo | 4 | ATG/CSA | 1 |
19 | 1 mo | 6 | ATG/CSA | 1.1 |
20 | 2 mo | 1 | ATG/CSA | 0.66 |
21 | 2 wk | 8 | ATG/CSA | 0.89 |
22 | 2 wk | 3 | ATG/CSA | 0.7 |
23 | 3 wk | 4 | ATG/CSA | 2.8* |
24 | 2 wk | 5 | ATG/CSA | 1.0 |
Patient . | Disease duration prior to treatment . | Transfusions prior to treatment, no. . | Treatment type . | MCF ratio . |
---|---|---|---|---|
1 | 3.5 mo | 4 | ATG/CSA | 1 |
2 | 5 mo | 19 | ATG/CSA | 0.58 |
3 | 3 mo | 4 | ATG/CSA | 1 |
4 | 10 y | 2 | CTX | 0.9 |
5 | 3 mo | 3 | ATG/CSA | 1 |
6 | 8 y | 4 | ATG/CSA | 0.52 |
7 | 4 mo | 20 | ATG/CSA | 0.36 |
8 | 8 y | 3 | CTX | 0.54 |
9 | 2.5 mo | 4 | CTX | 0.28 |
10 | 4 y | 11 | ATG/CSA | 0.58 |
11 | 3 mo | 2 | ATG/CSA | 0.39 |
12 | 3 mo | 9 | ATG/CSA | 1 |
13 | 3 mo | 3 | ATG/CSA | 1 |
14 | 3 wk | 3 | ATG/CSA | 1 |
15 | 1 mo | 2 | ATG/CSA | 0.7 |
16 | 2 wk | 4 | ATG/CSA | 0.8 |
17 | 3 mo | 5 | ATG/CSA | 1.2 |
18 | 2 mo | 4 | ATG/CSA | 1 |
19 | 1 mo | 6 | ATG/CSA | 1.1 |
20 | 2 mo | 1 | ATG/CSA | 0.66 |
21 | 2 wk | 8 | ATG/CSA | 0.89 |
22 | 2 wk | 3 | ATG/CSA | 0.7 |
23 | 3 wk | 4 | ATG/CSA | 2.8* |
24 | 2 wk | 5 | ATG/CSA | 1.0 |
Patient was scored as positive, remained positive following treatment, but responded to second course of immunotherapy.